CellCentric
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
About
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a novel oral p300/CBP inhibitor, for the treatment of multiple myeloma. The company recently completed an oversubscribed $220 million Series D financing round, which will be used to advance the development of inobrodib. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does CellCentric do?
CellCentric is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in Cambridge, England, United Kingdom and was founded in 2003. Public records show about 53 people and $375M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has CellCentric raised?
CellCentric has raised a total of $375M in funding. The most recent round on record is Series D.
Where is CellCentric headquartered?
CellCentric is headquartered in Cambridge, England, United Kingdom.
When was CellCentric founded?
CellCentric was founded in 2003.
What industry does CellCentric operate in?
CellCentric operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Medical.
How many employees does CellCentric have?
CellCentric has approximately 53 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.